TG Therapeutics, Inc. vs ADMA Biologics, Inc.: Annual Revenue Growth Compared

A Tale of Two Biotechs: Revenue Growth from 2014 to 2023

In the dynamic world of biotechnology, revenue growth is a key indicator of a company's success and potential. Over the past decade, ADMA Biologics, Inc. and TG Therapeutics, Inc. have showcased contrasting trajectories in their annual revenue growth. Starting in 2014, ADMA Biologics reported a modest revenue of approximately $5.9 million, which surged to an impressive $258 million by 2023. This represents a staggering growth of over 4,200%, highlighting ADMA's robust expansion and market penetration.

Conversely, TG Therapeutics experienced a more volatile journey. From a steady revenue of around $152,000 between 2014 and 2020, the company saw a dramatic increase to $233 million in 2023. This leap underscores TG Therapeutics' breakthrough in recent years, possibly due to successful product launches or strategic partnerships. These trends reflect the ever-evolving landscape of the biotech industry, where innovation and adaptability are paramount.